ImmunoPrecise Antibodies Ltd.
IPA
$0.4379
$0.01092.55%
NASDAQ
| 01/31/2025 | 10/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -3.51% | 16.71% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.51% | 16.71% | |||
| Cost of Revenue | 2.08% | -7.27% | |||
| Gross Profit | -7.89% | 46.30% | |||
| SG&A Expenses | 4.47% | -2.65% | |||
| Depreciation & Amortization | -2.36% | 1.45% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.16% | -8.26% | |||
| Operating Income | -11.23% | 37.22% | |||
| Income Before Tax | -670.62% | 35.75% | |||
| Income Tax Expenses | -472.29% | 34.60% | |||
| Earnings from Continuing Operations | -709.93% | 35.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -709.93% | 35.98% | |||
| EBIT | -11.23% | 37.22% | |||
| EBITDA | -19.13% | 46.68% | |||
| EPS Basic | -593.23% | 38.20% | |||
| Normalized Basic EPS | 9.84% | 37.98% | |||
| EPS Diluted | -593.23% | 38.20% | |||
| Normalized Diluted EPS | 9.84% | 37.98% | |||
| Average Basic Shares Outstanding | 16.77% | 3.68% | |||
| Average Diluted Shares Outstanding | 16.77% | 3.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||